Immunotherapy for brain tumors: understanding early successes and limitations

References

• Ostrom QT, Gittleman H, Xu J, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2009-2013. Neuro Oncol. 2016;18(suppl_5):v1–v75.
   PubMed Web of Science ®Google Scholar
• McDermott DF, Drake CG, Sznol M, et al. Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab. J Clin Oncol. 2015;33(18):2013–2020.
   PubMed Web of Science ®Google Scholar
• Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018–2028.
   PubMed Web of Science ®Google Scholar
• Farkona S, Diamandis EP, Blasutig IM. Cancer immunotherapy: the beginning of the end of cancer? BMC Med. 2016;14:73.
   PubMed Web of Science ®Google Scholar
• Khalil DN, Smith EL, Brentjens RJ, et al. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol. 2016;13(6):394.
   PubMed Web of Science ®Google Scholar
• Schuessler A, Smith C, Beagley L, et al. Autologous T-cell therapy for cytomegalovirus as a consolidative treatment for recurrent glioblastoma. Cancer Res. 2014;74(13):3466–3476.
   PubMed Web of Science ®Google Scholar
• Yee C, Thompson JA, Byrd D, et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A. 2002;99(25):16168–16173.
   PubMed Web of Science ®Google Scholar
• Lim O, Jung MY, Hwang YK, et al. Present and future of allogeneic natural killer cell therapy. Front Immunol. 2015;6:286.
   PubMed Web of Science ®Google Scholar
• Stromnes IM, Schmitt TM, Chapuis AG, et al. Re-adapting T cells for cancer therapy: from mouse models to clinical trials. Immunol Rev. 2014;257(1):145–164.
   PubMed Web of Science ®Google Scholar
• Sadelain M, Brentjens R, Riviere I. The basic principles of chimeric antigen receptor design. Cancer Discov. 2013;3(4):388–398.
   PubMed Web of Science ®Google Scholar
• Tasian SK, Gardner RA. CD19-redirected chimeric antigen receptor-modified T cells: a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL). Ther Adv Hematol. 2015;6(5):228–241.
   PubMed Web of Science ®Google Scholar
• Kakarla S, Gottschalk S. CAR T cells for solid tumors: armed and ready to go? Cancer J. 2014;20(2):151–155.
   PubMed Web of Science ®Google Scholar
• Newick K, Moon E, Albelda SM. Chimeric antigen receptor T-cell therapy for solid tumors. Mol Ther Oncolytics. 2016;3:16006.
   PubMed Web of Science ®Google Scholar
• Klebanoff CA, Rosenberg SA, Restifo NP. Prospects for gene-engineered T cell immunotherapy for solid cancers. Nat Med. 2016;22(1):26–36.
   PubMed Web of Science ®Google Scholar
• Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 2016;127(26):3321–3330.
   PubMed Web of Science ®Google Scholar
• Bedoya F, Frigault MJ, Maus MV. The flipside of the power of engineered T cells: observed and potential toxicities of genetically modified T cells as therapy. Mol Ther. 2017;25(2):314–320.
   PubMed Web of Science ®Google Scholar
• Greco R, Oliveira G, Stanghellini MT, et al. Improving the safety of cell therapy with the TK-suicide gene. Front Pharmacol. 2015;6:95.
   PubMed Web of Science ®Google Scholar
• Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 2015;161(2):205–214.
   PubMed Web of Science ®Google Scholar
• Crane CA, Han SJ, Ahn B, et al. Individual patient-specific immunity against high-grade glioma after vaccination with autologous tumor derived peptides bound to the 96 KD chaperone protein. Clinl Cancer Res. 2013;19(1):205–214.
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411–422.
   PubMed Web of Science ®Google Scholar
• Pampena MB, Levy EM. Natural killer cells as helper cells in dendritic cell cancer vaccines. Front Immunol. 2015;6:13.
   PubMed Web of Science ®Google Scholar
• Stieber D, Golebiewska A, Evers L, et al. Glioblastomas are composed of genetically divergent clones with distinct tumourigenic potential and variable stem cell-associated phenotypes. Acta Neuropathol. 2014;127(2):203–219.
   PubMed Web of Science ®Google Scholar
• Spencer DA, Young JS, Kanojia D, et al. Unlocking the promise of oncolytic virotherapy in glioma: combination with chemotherapy to enhance efficacy. Ther Deliv. 2015;6(4):453–468.
   PubMed Web of Science ®Google Scholar
• Butowski N, Colman H, De Groot JF, et al. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro Oncol. 2016;18(4):557–564.
   PubMed Web of Science ®Google Scholar
• Moyes KW, Lieberman NA, Kreuser SA, et al. Genetically engineered macrophages: a potential platform for cancer immunotherapy. Hum Gene Ther. 2017;28(2):200–215.
   PubMed Web of Science ®Google Scholar
• Ostrom QT, Bauchet L, Davis FG, et al. The epidemiology of glioma in adults: a “state of the science” review. Neuro Oncol. 2014;16(7):896–913.
   PubMed Web of Science ®Google Scholar
• Correa DD. Neurocognitive function in brain tumors. Curr Neurol Neurosci Rep. 2010;10(3):232–239.
   PubMed Web of Science ®Google Scholar
• Klein M, Engelberts NH, van der Ploeg HM, et al. Epilepsy in low-grade gliomas: the impact on cognitive function and quality of life. Ann Neurol. 2003;54(4):514–520.
   PubMed Web of Science ®Google Scholar
• Klein M, Heimans JJ, Aaronson NK, et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study. Lancet. 2002;360(9343):1361–1368.
   PubMed Web of Science ®Google Scholar
• Larjavaara S, Mantyla R, Salminen T, et al. Incidence of gliomas by anatomic location. Neuro Oncol. 2007;9(3):319–325.
   PubMed Web of Science ®Google Scholar
• Smoll NR, Gautschi OP, Schatlo B, et al. Relative survival of patients with supratentorial low-grade gliomas. Neuro Oncol. 2012;14(8):1062–1069.
   PubMed Web of Science ®Google Scholar
• Buckner J, Giannini C, Eckel-Passow J, et al. Management of diffuse low-grade gliomas in adults - use of molecular diagnostics. Nat Rev Neurol. 2017;13(6):340–351.
   PubMed Web of Science ®Google Scholar
• Shaw EG, Wang M, Coons SW, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. J Clin Oncol. 2012;30(25):3065–3070.
   PubMed Web of Science ®Google Scholar
• Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol. 2013;31(3):337–343.
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, Van Den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–996.
   PubMed Web of Science ®Google Scholar
• Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001;95(2):190–198.
   PubMed Web of Science ®Google Scholar
• McGirt MJ, Mukherjee D, Chaichana KL, et al. Association of surgically acquired motor and language deficits on overall survival after resection of glioblastoma multiforme. Neurosurgery. 2009;65(3):463–469; discussion 469–470.
   Web of Science ®Google Scholar
• Yong RL, Lonser RR. Surgery for glioblastoma multiforme: striking a balance. World Neurosurg. 2011;76(6):528–530.
   PubMed Web of Science ®Google Scholar
• Kostaras X, Cusano F, Kline GA, et al. Use of dexamethasone in patients with high-grade glioma: a clinical practice guideline. Curr Oncol. 2014;21(3):e493–503.
   PubMed Web of Science ®Google Scholar
• Taphoorn MJ, Stupp R, Coens C, et al. Health-related quality of life in patients with glioblastoma: a randomised controlled trial. Lancet Oncol. 2005;6(12):937–944.
   PubMed Web of Science ®Google Scholar
• Taphoorn MJ, van den Bent MJ, Mauer ME, et al. Health-related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: results of a European Organisation for Research and Treatment of Cancer randomized clinical trial. J Clin Oncol. 2007;25(36):5723–5730.
   PubMed Web of Science ®Google Scholar
• Wang M, Cairncross G, Shaw E, et al. Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402. Int J Radiat Oncol Biol Phys. 2010;77(3):662–669.
   PubMed Web of Science ®Google Scholar
• Lieberman NA, Moyes KW, Crane CA. Developing immunotherapeutic strategies to target brain tumors. Expert Rev Anticancer Ther. 2016;16(7):775–788.
   PubMed Web of Science ®Google Scholar
• Oji Y, Hashimoto N, Tsuboi A, et al. Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide. Int J Cancer. 2016;139(6):1391–1401.
   PubMed Web of Science ®Google Scholar
• Batich KA, Reap EA, Archer GE, et al. Long-term survival in glioblastoma with cytomegalovirus pp65-targeted vaccination. Clinl Cancer Res. 2017;23(8):1898–1909.
   PubMed Web of Science ®Google Scholar
• Reardon D, Sampson JH, Sahebjam S, et al. Safety and activity of nivolumab (nivo) monotherapy and nivo in combination with ipilimumab (ipi) in recurrent glioblastoma (GBM): updated results from checkmate-143. J Clin Oncol. 2016;34(suppl;abstr 2014).
   Google Scholar
• Bouffet E, Larouche V, Campbell BB, et al. Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency. J Clin Oncol. 2016;34(19):2206–2211.
   PubMed Web of Science ®Google Scholar
• Johanns TM, Miller CA, Dorward IG, et al. Immunogenomics of hypermutated glioblastoma: a patient with germline pole deficiency treated with checkpoint blockade immunotherapy. Cancer Discov. 2016;6(11):1230–1236.
   PubMed Web of Science ®Google Scholar
• Chow KK, Hara W, Lim M, et al. Combining immunotherapy with radiation for the treatment of glioblastoma. J Neurooncol. 2015;123(3):459–464.
   PubMed Web of Science ®Google Scholar
• Brown CE, Alizadeh D, Starr R, et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N Engl J Med. 2016;375(26):2561–2569.
   PubMed Web of Science ®Google Scholar
• Sands SA, Zhou T, O’Neil SH, et al. Long-term follow-up of children treated for high-grade gliomas: children’s oncology group L991 final study report. J Clin Oncol. 2012;30(9):943–949.
   PubMed Web of Science ®Google Scholar
• Tallen G, Resch A, Calaminus G, et al. Strategies to improve the quality of survival for childhood brain tumour survivors. Eur J Paediatr Neurol. 2015;19(6):619–639.
   PubMed Web of Science ®Google Scholar
• Gajjar A, Bowers DC, Karajannis MA, et al. Pediatric brain tumors: innovative genomic information is transforming the diagnostic and clinical landscape. J Clin Oncol. 2015;33(27):2986–2998.
   PubMed Web of Science ®Google Scholar
• Johnson KJ, Cullen J, Barnholtz-Sloan JS, et al. Childhood brain tumor epidemiology: a brain tumor epidemiology consortium review. Cancer Epidemiol Biomarkers Prev. 2014;23(12):2716–2736.
   PubMed Web of Science ®Google Scholar
• Tulla M, Berthold F, Graf N, et al. Incidence, trends, and survival of children with embryonal tumors. Pediatrics. 2015;136(3):e623–632.
   PubMed Web of Science ®Google Scholar
• Wells EM, Packer RJ. Pediatric brain tumors. Continuum (Minneap Minn). 2015;21(2 Neuro–oncology):373–396.
   PubMedGoogle Scholar
• Sturm D, Pfister SM, Jones DTW. Pediatric gliomas: current concepts on diagnosis, biology, and clinical management. J Clin Oncol. 2017;35(21):2370–2377.
   PubMed Web of Science ®Google Scholar
• Fangusaro J. Pediatric high grade glioma: a review and update on tumor clinical characteristics and biology. Front Oncol. 2012;2:105.
   PubMedGoogle Scholar
• Warren KE. Diffuse intrinsic pontine glioma: poised for progress. Front Oncol. 2012;2:205.
   PubMedGoogle Scholar
• Monje M, Mitra SS, Freret ME, et al. Hedgehog-responsive candidate cell of origin for diffuse intrinsic pontine glioma. Proc Natl Acad Sci U S A. 2011;108(11):4453–4458.
   PubMed Web of Science ®Google Scholar
• Kool M, Korshunov A, Remke M, et al. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol. 2012;123(4):473–484.
   PubMed Web of Science ®Google Scholar
• Hill RM, Kuijper S, Lindsey JC, et al. Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease. Cancer Cell. 2015;27(1):72–84.
   PubMed Web of Science ®Google Scholar
• Sabel M, Fleischhack G, Tippelt S, et al. Relapse patterns and outcome after relapse in standard risk medulloblastoma: a report from the HIT-SIOP-PNET4 study. J Neurooncol. 2016;129(3):515–524.
   PubMed Web of Science ®Google Scholar
• Aarsen FK, Paquier PF, Arts WF, et al. Cognitive deficits and predictors 3 years after diagnosis of a pilocytic astrocytoma in childhood. J Clin Oncol. 2009;27(21):3526–3532.
   PubMed Web of Science ®Google Scholar
• Aarsen FK, Van Dongen HR, Paquier PF, et al. Long-term sequelae in children after cerebellar astrocytoma surgery. Neurology. 2004;62(8):1311–1316.
   PubMed Web of Science ®Google Scholar
• Lanier JC, Abrams AN. Posterior fossa syndrome: review of the behavioral and emotional aspects in pediatric cancer patients. Cancer. 2017;123(4):551–559.
   PubMed Web of Science ®Google Scholar
• Robertson PL, Muraszko KM, Holmes EJ, et al. Incidence and severity of postoperative cerebellar mutism syndrome in children with medulloblastoma: a prospective study by the Children’s Oncology Group. J Neurosurg. 2006;105(6 Suppl):444–451.
   PubMed Web of Science ®Google Scholar
• Fauquette W, Amourette C, Dehouck MP, et al. Radiation-induced blood-brain barrier damages: an in vitro study. Brain Res. 2012;1433:114–126.
   PubMed Web of Science ®Google Scholar
• Hue CD, Cho FS, Cao S, et al. Dexamethasone potentiates in vitro blood-brain barrier recovery after primary blast injury by glucocorticoid receptor-mediated upregulation of ZO-1 tight junction protein. J Cereb Blood Flow Metab. 2015;35(7):1191–1198.
   PubMed Web of Science ®Google Scholar
• Drozdowicz LB, Bostwick JM. Psychiatric adverse effects of pediatric corticosteroid use. Mayo Clin Proc. 2014;89(6):817–834.
   PubMed Web of Science ®Google Scholar
• Dietrich J, Rao K, Pastorino S, et al. Corticosteroids in brain cancer patients: benefits and pitfalls. Expert Rev Clin Pharmacol. 2011;4(2):233–242.
   PubMedGoogle Scholar
• Lawrence YR, Li XA, El Naqa I, et al. Radiation dose-volume effects in the brain. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S20–27.
   PubMed Web of Science ®Google Scholar
• Fouladi M, Chintagumpala M, Laningham FH, et al. White matter lesions detected by magnetic resonance imaging after radiotherapy and high-dose chemotherapy in children with medulloblastoma or primitive neuroectodermal tumor. J Clin Oncol. 2004;22(22):4551–4560.
   PubMed Web of Science ®Google Scholar
• Packer RJ, Goldwein J, Nicholson HS, et al. Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: a Children’s Cancer Group Study. J Clin Oncol. 1999;17(7):2127–2136.
   PubMed Web of Science ®Google Scholar
• von Bueren AO, Von Hoff K, Benesch M, et al. Dose reductions of vincristine in children with medulloblastoma treated in the maintenance arm of the prospective multicenter trial HIT’91. Klin Padiatr. 2009;221(6):396–397.
   PubMed Web of Science ®Google Scholar
• Peleva E, Emami N, Alzahrani M, et al. Incidence of platinum-induced ototoxicity in pediatric patients in Quebec. Pediatr Blood Cancer. 2014;61(11):2012–2017.
   PubMed Web of Science ®Google Scholar
• Schreiber JE, Gurney JG, Palmer SL, et al. Examination of risk factors for intellectual and academic outcomes following treatment for pediatric medulloblastoma. Neuro Oncol. 2014;16(8):1129–1136.
   PubMed Web of Science ®Google Scholar
• Simon AK, Hollander GA, McMichael A. Evolution of the immune system in humans from infancy to old age. Proc Biol Sci. 2015;282(1821):20143085.
   PubMed Web of Science ®Google Scholar
• Chalmers ZR, Connelly CF, Fabrizio D, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9(1):34.
   PubMed Web of Science ®Google Scholar
• Merchant MS, Wright M, Baird K, et al. Phase I clinical trial of ipilimumab in pediatric patients with advanced solid tumors. Clinl Cancer Res. 2016;22(6):1364–1370.
   PubMed Web of Science ®Google Scholar
• Warren K, Bent R, Wolters PL, et al. A phase 2 study of pegylated interferon alpha-2b (PEG-Intron((R))) in children with diffuse intrinsic pontine glioma. Cancer. 2012;118(14):3607–3613.
   PubMed Web of Science ®Google Scholar
• Pollack IF, Jakacki RI, Butterfield LH, et al. Antigen-specific immunoreactivity and clinical outcome following vaccination with glioma-associated antigen peptides in children with recurrent high-grade gliomas: results of a pilot study. J Neurooncol. 2016;130(3):517–527.
   PubMed Web of Science ®Google Scholar
• Pollack IF, Jakacki RI, Butterfield LH, et al. Immune responses and outcome after vaccination with glioma-associated antigen peptides and poly-ICLC in a pilot study for pediatric recurrent low-grade gliomas. Neuro Oncol. 2016;18(8):1157–1168.
   PubMed Web of Science ®Google Scholar
• Pollack IF, Jakacki RI, Butterfield LH, et al. Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstem and nonbrainstem gliomas. J Clin Oncol. 2014;32(19):2050–2058.
   PubMed Web of Science ®Google Scholar
• Polyzoidis S, Ashkan K. DCVax(R)-L–developed by Northwest Biotherapeutics. Hum Vaccin Immunother. 2014;10(11):3139–3145.
   PubMed Web of Science ®Google Scholar
• Van Gool SW, Holm S, Rachor J, et al. Immunotherapy in atypical teratoid-rhabdoid tumors: data from a survey of the HGG-Immuno Group. Cytotherapy. 2016;18(9):1178–1186.
   PubMed Web of Science ®Google Scholar
• Friedman GK, Moore BP, Nan L, et al. Pediatric medulloblastoma xenografts including molecular subgroup 3 and CD133+ and CD15+ cells are sensitive to killing by oncolytic herpes simplex viruses. Neuro Oncol. 2016;18(2):227–235.
   PubMed Web of Science ®Google Scholar
• Studebaker AW, Kreofsky CR, Pierson CR, et al. Treatment of medulloblastoma with a modified measles virus. Neuro Oncol. 2010;12(10):1034–1042.
   PubMed Web of Science ®Google Scholar
• Zhu X, McDowell MM, Newman WC, et al. Severe cerebral edema following nivolumab treatment for pediatric glioblastoma: case report. J Neurosurg Pediatr. 2017;19(2):249–253.
   PubMed Web of Science ®Google Scholar
• Le DT, Durham JN, Smith KN, et al. Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017.
   Web of Science ®Google Scholar
• Pham CD, Flores C, Yang C, et al. Differential immune microenvironments and response to immune checkpoint blockade among molecular subtypes of murine medulloblastoma. Clinl Cancer Res. 2016;22(3):582–595.
   PubMed Web of Science ®Google Scholar
• Heczey A, Louis CU, Savoldo B, et al. CAR T cells administered in combination with lymphodepletion and PD-1 inhibition to patients with neuroblastoma. Mol Ther. 2017 Sep 6;25(9):2214–2224.
   PubMed Web of Science ®Google Scholar
• Agarwalla P, Barnard Z, Fecci P, et al. Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors. J Immunotherapy. 2012;35(5):385–389.
   PubMed Web of Science ®Google Scholar
• Antonios JP, Soto H, Everson RG, et al. PD-1 blockade enhances the vaccination-induced immune response in glioma. JCI Insight. 2016;1:10.
   Web of Science ®Google Scholar
• Cherkassky L, Morello A, Villena-Vargas J, et al. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest. 2016;126(8):3130–3144.
   PubMed Web of Science ®Google Scholar
• John LB, Devaud C, Duong CP, et al. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clinl Cancer Res. 2013;19(20):5636–5646.
   PubMed Web of Science ®Google Scholar
• Shi L, Lin H, Li G, et al. Cisplatin enhances NK cells immunotherapy efficacy to suppress HCC progression via altering the androgen receptor (AR)-ULBP2 signals. Cancer Letters. 2016;373(1):45–56.
   PubMed Web of Science ®Google Scholar
• Curti A, Ruggeri L, Parisi S, et al. Larger size of donor alloreactive NK cell repertoire correlates with better response to NK cell immunotherapy in elderly acute myeloid leukemia patients. Clin Cancer Res. 2016;22(8):1914–1921.
   PubMed Web of Science ®Google Scholar
• Topfer K, Cartellieri M, Michen S, et al. DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy. J Immunol. 2015;194(7):3201–3212.
   PubMed Web of Science ®Google Scholar
• Heczey A, Liu D, Tian G, et al. Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy. Blood. 2014;124(18):2824–2833.
   PubMed Web of Science ®Google Scholar
• Sentman CL, Meehan KR. NKG2D CARs as cell therapy for cancer. Cancer J. 2014;20(2):156–159.
   PubMed Web of Science ®Google Scholar